GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Clinical trials for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy combo targets rare cancers left behind by progress
Disease control Recruiting nowThis trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of rare advanced cancers that have not responded to standard treatment. The goal is to see if the combo can shrink tumors or stop them from growing. About 154 parti…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 23, 2026 19:46 UTC
-
Radioactive drug RYZ401 takes aim at neuroendocrine tumors in first human trial
Disease control Recruiting nowThis early-stage trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers radiation directly to cancer cells. The study will enroll about 104 adults to find the sa…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Alpha-Particle therapy targets Hard-to-Treat tumors in first human trial
Disease control Recruiting nowThis study tests a new drug called [212Pb]VMT-α-NET, which delivers a powerful alpha particle directly to tumor cells that have a specific marker (SSTR2). The trial involves 300 adults with advanced neuroendocrine tumors or meningioma that cannot be removed by surgery. The goal i…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
New registry tracks PRRT outcomes for neuroendocrine cancer patients
Disease control Recruiting nowThis study is tracking 50 adults with neuroendocrine tumors who are receiving peptide receptor radionuclide therapy (PRRT). Researchers are collecting data on patient characteristics, treatment responses, survival, and side effects. The goal is to better understand who benefits f…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 22, 2026 11:57 UTC
-
Radioactive drug plus surgery: new hope for neuroendocrine cancer?
Disease control Recruiting nowThis early-phase study tests whether giving a radioactive drug (Lutathera) before and after surgery is safe and feasible for people with advanced neuroendocrine tumors that have spread to the liver or lymph nodes. About 10 participants will receive two cycles of the drug, then un…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New hope for gut cancer patients who failed standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors of the gut or pancreas that cannot be removed by surgery and have grown after prior treatment with a type of radiation therapy (177Lu-SSA). The study has two parts: first, finding the right do…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC
-
New imaging study aims to personalize radiation therapy for GEP-NETs
Knowledge-focused Recruiting nowThis study is looking at people with a rare type of tumor called GEP-NET that has spread and is growing. Participants will get special PET-MRI scans before, during, and after a standard treatment called targeted radiation therapy (PRRT). The goal is to find imaging markers that c…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:58 UTC
-
Ultrasound breakthrough: predicting cancer therapy success without needles
Knowledge-focused Recruiting nowThis study is testing whether a special type of ultrasound (called D-CEUS) can predict if a targeted radiation therapy (PRRT) is working in people with advanced neuroendocrine tumors of the pancreas or gut. About 30 adults with these tumors will get D-CEUS scans before, during, a…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:52 UTC
-
Could diet be key to better outcomes for Slow-Growing tumors?
Knowledge-focused Recruiting nowThis study looks at whether nutritional status is linked to prognosis in adults with gastroenteropancreatic neuroendocrine tumors (NETs), which are slow-growing cancers of the digestive system. Researchers will assess malnutrition in 100 participants aged 18 to 70 who have been t…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:24 UTC